Product image of Inegy (Simvastatin, Ezetimibe) supplied by GNH India

Inegy

Active Ingredient:
Simvastatin, Ezetimibe
Origin:
EU

Inegy (Simvastatin, Ezetimibe)

Simvastatin/Ezetimibe, the active ingredient in Inegy, is a statin and cholesterol absorption inhibitor combination presented as a tablet for oral use. It lowers elevated cholesterol levels and is prescribed for adults with primary hypercholesterolemia, mixed dyslipidemia, or familial hypercholesterolemia.

GNH India supplies Inegy as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to EU quality standards and provides reliable global distribution.

Manufacturer / TM Owner

N.V. Organon

1
Pack/s
This product is added to your enquiry list

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

A minimum order value applies. Our team will confirm the exact amount or quantity after reviewing your requirements.

Indications & Clinical Uses

Inegy is used to manage lipid disorders by targeting cholesterol synthesis and absorption pathways.

  • Hypercholesterolemia: reduces LDL‑cholesterol and total cholesterol levels.
  • Mixed dyslipidemia: improves the overall lipid profile, lowering LDL and triglycerides while modestly raising HDL.
  • Familial hypercholesterolemia: provides additional LDL‑cholesterol reduction when statin monotherapy is insufficient.

How It Works

  • Simvastatin inhibits HMG‑CoA reductase, the key enzyme in hepatic cholesterol biosynthesis, decreasing endogenous cholesterol production. Ezetimibe blocks the Niemann‑Pick C1‑like 1 (NPC1L1) transporter in the intestinal brush border, reducing absorption of dietary and biliary cholesterol. The combined effect leads to lower circulating low‑density lipoprotein (LDL) cholesterol and total cholesterol, enhancing overall lipid control.

Side Effects

Inegy may cause a range of adverse reactions, which are categorized by frequency and severity.

Common Side Effects

  • Headache: mild to moderate intensity.
  • Myalgia: muscle aches without weakness.
  • Gastrointestinal discomfort: nausea, abdominal pain or diarrhea.
  • Elevated liver enzymes: mild transaminase increase.
  • Fatigue: general tiredness.

Serious or Rare Side Effects

  • Rhabdomyolysis: severe muscle breakdown with possible renal impairment.
  • Hepatotoxicity: marked elevation of liver enzymes or hepatitis.
  • Severe allergic reactions: rash, angioedema, or anaphylaxis.

Precautions & Warnings

Before prescribing Inegy, clinicians should consider several precautionary measures to ensure patient safety.

  • Liver function monitoring: assess baseline transaminases and repeat periodically.
  • Renal impairment assessment: adjust therapy in severe renal dysfunction.
  • Drug‑induced myopathy risk: avoid in patients with a history of statin‑related muscle toxicity.
  • Pregnancy and lactation: contraindicated unless benefits outweigh risks; generally avoided.
  • Concomitant medications: review for potential interactions, especially CYP3A4 inhibitors.
  • Store at ambient temperature: keep below 25 °C, in original packaging, protected from moisture and light.

Avoid Interactions

Inegy interacts with several medicines; the significance of each interaction determines clinical management.

Major Interactions (Avoid)

  • Strong CYP3A4 inhibitors (e.g., clarithromycin, itraconazole): can markedly increase simvastatin exposure.
  • Gemfibrozil: raises risk of myopathy and rhabdomyolysis.
  • Cyclosporine: enhances both simvastatin and ezetimibe plasma levels, increasing toxicity risk.
  • HIV protease inhibitors: potentiate simvastatin concentrations, leading to serious adverse events.

Moderate Interactions (Monitor Closely)

  • Anticoagulants (warfarin): may require INR monitoring due to altered metabolism.
  • Digoxin: ezetimibe can increase digoxin levels; monitor for toxicity.
  • Niacin: combined use may increase risk of muscle‑related side effects.
  • Fibrates (other than gemfibrozil): may modestly raise myopathy risk; observe symptoms.

Frequently Asked Questions

Inegy is prescribed to lower elevated cholesterol levels in adults with primary hypercholesterolemia, mixed dyslipidemia, or familial hypercholesterolemia. By reducing low‑density lipoprotein (LDL) cholesterol, it helps lower the risk of cardiovascular events associated with abnormal lipid profiles.

Simvastatin blocks HMG‑CoA reductase, decreasing the liver’s production of cholesterol. Ezetimibe inhibits the NPC1L1 transporter in the intestine, reducing the absorption of dietary and biliary cholesterol. The dual action results in a greater reduction of circulating LDL cholesterol than either agent alone.

The dose of Inegy is individualized by the prescribing clinician based on the patient’s lipid profile, treatment goals, and tolerance. Dosage adjustments may be made during therapy, but the specific regimen should always follow the prescriber’s recommendation.

Inegy is generally not recommended for use during pregnancy or while breastfeeding unless the potential benefit justifies the potential risk to the fetus or infant. Clinicians should evaluate the risk‑benefit ratio and consider alternative therapies when possible.

To order Inegy, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements), and necessary import documentation.

Inegy combines a statin (simvastatin) with a cholesterol absorption inhibitor (ezetimibe), offering greater LDL‑cholesterol reduction than a statin alone. This dual approach can be advantageous for patients who need additional lipid control without escalating statin dose, and it may reduce the likelihood of statin‑related side effects compared with high‑dose monotherapy.

Inegy tablets should be stored at ambient temperature, below 25 °C, in the original packaging to protect from moisture and light. Keep the product out of reach of children and avoid storing in humid or excessively hot environments.

Inegy is taken orally, usually once daily, with or without food as directed by the prescriber. The tablet should be swallowed whole with a glass of water and not crushed or chewed unless specifically instructed.

The most serious risks include rhabdomyolysis (severe muscle breakdown) and hepatotoxicity (significant liver enzyme elevation or hepatitis). Patients should report unexplained muscle pain, weakness, dark urine, or signs of liver dysfunction such as jaundice or persistent fatigue to their healthcare provider promptly.

Inegy should be avoided in individuals with active liver disease, unexplained persistent elevations of serum transaminases, known hypersensitivity to simvastatin, ezetimibe, or any excipients. It is also contraindicated in patients taking strong CYP3A4 inhibitors or gemfibrozil due to the heightened risk of serious muscle toxicity.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated:

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.

Related Products

Other formulations containing Simvastatin, Ezetimibe

A

A
A

A
A

A
A

A

Browse all products →

Ordering Process

Simple, Secure, and Seamless

Learn how our streamlined ordering process guarantees fast, compliant, and reliable access to essential medicines worldwide.

Quote request form

01

Submit Quote Request Form

Tell us what medications you need by filling out our simple form and uploading a valid document.

Price estimate review

02

We Review & Send Estimate

Our licensed pharmacists will verify your details and provide you with a detailed cost estimate.

Secure payment

03

Confirm & Make Payment

Discuss any queries, approve the estimate, and complete your payment.

Worldwide delivery

04

Get Delivered

Your medicines, safely packed and delivered to your door or nearest airport — hassle-free.

Regulatory recognitions

Quality You Can Trust

Our internationally recognized certifications underscore our commitment to safety, quality, and excellence.

SGS GSDP Certification

GSDP Compliant from SGS

URS ISO 9001

URS ISO 9001 Certification

FDA Maharashtra

Licensed by FDA Maharashtra

IEC License DGFT

IEC License issued by DGFT